These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6644555)

  • 1. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1983 Jun; 11(3):303-19. PubMed ID: 6644555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1981 Oct; 9(5):635-51. PubMed ID: 7334463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):553-71. PubMed ID: 7229908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
    Sheiner LB
    Drug Metab Rev; 1984; 15(1-2):153-71. PubMed ID: 6745080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.
    Sheiner LB; Grasela TH
    Drug Metab Rev; 1984; 15(1-2):293-303. PubMed ID: 6547663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.
    Steimer JL; Mallet A; Golmard JL; Boisvieux JF
    Drug Metab Rev; 1984; 15(1-2):265-92. PubMed ID: 6745083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
    Ette EI; Onyiah LC
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences in the application of NONMEM to pharmacokinetic data analysis.
    Flühler H; Huber H; Widmer E; Brechbühler S
    Drug Metab Rev; 1984; 15(1-2):317-39. PubMed ID: 6547665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
    White DB; Walawander CA; Tung Y; Grasela TH
    J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined proportional and additive residual error models in population pharmacokinetic modelling.
    Proost JH
    Eur J Pharm Sci; 2017 Nov; 109S():S78-S82. PubMed ID: 28512056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic data and parameter estimation based on their first two statistical moments.
    Beal SL
    Drug Metab Rev; 1984; 15(1-2):173-93. PubMed ID: 6745081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
    Ling J; Qian LX; Ding JJ; Jiao Z
    Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.
    Sheiner LB; Beal SL
    J Pharm Sci; 1982 Dec; 71(12):1344-8. PubMed ID: 7153881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Digoxin in Duchenne Muscular Dystrophy (DMD) Patients.
    Tateishi M; Ebihara A
    Am J Ther; 1994 Aug; 1(2):144-149. PubMed ID: 11835079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
    Yukawa E; Mine H; Higuchi S; Aoyama T
    J Pharm Pharmacol; 1992 Sep; 44(9):761-5. PubMed ID: 1360530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies.
    Upton RA; Thiercelin JF; Moore JK; Riegelman S
    J Pharmacokinet Biopharm; 1982 Apr; 10(2):135-46. PubMed ID: 7120044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation studies of errors of parameter estimates in pharmacokinetics.
    Betzien G; Kaufmann B; Schneider B; Ritschel WA
    Arzneimittelforschung; 1985; 35(1):7-14. PubMed ID: 3838673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.